The carbon footprint of diagnostic delays in asthma

Footnotes

This manuscript has recently been accepted for publication in the ERJ Open Research. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article.

Conflict of interest: LP, LD, SEL, SLP, and MD declare no conflicts of interest.

Conflict of interest:CCP: reports speaker honoraria from AstraZeneca, GlaxoSmithKline, and Sanofi-Regeneron; he received consultancy fees from AstraZeneca, GlaxoSmithKline, and Sanofi-Regeneron.

Conflict of interest: SL reports speaker honoraria from AstraZeneca outside of the submitted work.

Conflict of interest: FAV reports speaker honoraria from AstraZeneca, Sanofi-Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis outside of the submitted work.

Conflict of interest: PL reports speaker honoraria from AstraZeneca, Sanofi-Regeneron, GlaxoSmithKline, Boehringer Ingelheim and Novartis outside of the submitted work: he received consultancy fees from AstraZeneca, GlaxoSmithKline, and Sanofi-Regeneron.

Conflict of interest: SC reports the following: he has received non-restricted research grants from the NIHR Oxford BRC, the Quebec Respiratory Health Research Network, the Fondation Québécoise en Santé Respiratoire, the Academy of Medical Sciences, AstraZeneca, bioMérieux, and Sanofi-Genyme-Regeneron; he is the holder of the Association Pulmonaire du Québec's Research Chair in Respiratory medicine and is a Clinical research scholar of the Fonds de recherche du Québec; he received speaker honoraria from AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, and Valeo Pharma; he received consultancy fees for FirstThought, AstraZeneca, GlaxoSmithKline, Sanofi-Regeneron, Access Biotechnology and Access Industries; he has received sponsorship to attend/speak at international scientific meetings by/for AstraZeneca and Sanofi-Regeneron. He is an advisory board member and will have stock options for Biometry Inc – a company which is developing a FeNO device (myBiometry). He advised the Institut national d'excellence en santé et services sociaux (INESSS) for an update of the asthma general practice information booklet for general practitioners.